All In Biotech

Drug Trial Radar · NCT04591405

Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11

Last checked: Nov 20, 2026Latest source record: Oct 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 11,999 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

11,999

Actual

Start

Oct 12, 2020

Primary completion

Jul 1, 2024

Study completion Jul 1, 2024

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Hubei Provincial Center for Disease Control and Prevention
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 11 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Mumps is an acute infectious respiratory disease caused by the mumps virus (MuV), which occurs mainly in children and adolescents. Its main clinical symptoms were parotid gland suppurative swelling and pain with fever. The pathological changes and harm caused by mumps was not only confined to the parotid gland, on the contrary, the social harm caused by serious complications cannot be ignored. As mumps is a vaccine-preventable infectious disease, vaccination is a fundamental strategy for controlling mumps. So far, there are 13 genotypes of MuV. Based on the analysis of molecular epidemiology, the main epidemic strain of MuV in China was the F genotype. The commonly used vaccine strains represented only a small number of known genotypes, e.g. Jeryl-Lynn (JL) and Rubini strains, which belong to type A, Urabe strain belongs to type B, and L-Zagreb strains belongs to type D. Virus seed of Live Attenuated Mumps Vaccine (Human diploid cell) developed by the institute was SP-A strain, which was the first separation and preparation of the attenuated mumps viruses in China. SP-A belongs to F genotype, which was the domestic epidemic genotype. In addition, the cell substrate prepared for vaccine was human diploid cell (KMB-17 strain), which is much safer to use. The results of phase I and II clinical trials showed that the vaccine possessed good immunogenicity and good antigenic cross-reactivity in infants (8-24 months old).

Conditions

  • Epidemic Parotitis, Mumps

Interventions

  • Attenuated Mumps vaccine (KMB-17) in phase II and IIIBiological

    ≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 360 children (5-11 years old) on 0 day

  • Placebo in phase IIBiological

    Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day

  • Attenuated Mumps vaccine (KMB-17) in phase IIIBiological

    ≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 5640 children (5-11 years old) on 0 day

  • Placebo in phase IIIBiological

    Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase II: Positive conversion rate of MuV hemagglutination inhibition antibody of Muv VaccineTime frame: 28 day after the vaccination
  2. Phase II: Positive conversion rate of MuV neutralization antibody of MuV VaccineTime frame: 28 day after the vaccination
  3. Phase III: The protective effect of the MuV vaccine group compared with the placebo group in preventing mumps according with the protocolTime frame: within 12 months after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hubei Provincial Center for Disease Control and Prevention

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.